Apexigen is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer.


Recent advances in cancer immunology have increased our understanding of the mechanisms that cancer cells use to either avoid detection by or to de-activate the immune system. Novel immuno-oncology drugs are designed specifically to block immune suppression induced by tumors, or to actively initiate and augment an immune response against tumors. Manipulating the body’s immune system can lead to elimination of tumors and prevention of tumor recurrence (for a long-lasting cure).

Apexigen’s Immuno-oncology Strategy

Apexigen is focused on discovering and developing innovative drugs that enhance tumor-specific immunity. The use of its APXiMAB™ platform  enables Apexigen to discover antibodies with unique attributes against known and novel immune system targets. These antibodies have demonstrated the potential to become the next generation of cancer therapies as we progress toward the ultimate cure for cancer.


March 26, 2020
Apexigen To Present At The Upcoming 2020 Solebury Trout Virtual Investor Conference

March 24, 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline

February 27, 2020
Apexigen To Present At Upcoming Investor Conferences

December 6, 2019
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development

October 16, 2019
Apexigen’s CEO, Xiaodong Yang, Recognized Among 100 Most Intriguing Entrepreneurs at Goldman Sachs 2019 Builders + Innovators Summit

October 16, 2019
Apexigen to Present at the 2019 Solebury Trout Private Company Showcase

Read more news.